<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005595</url>
  </required_header>
  <id_info>
    <org_study_id>NCI 99H5</org_study_id>
    <secondary_id>NU-99H5</secondary_id>
    <secondary_id>NCI-T99-0093</secondary_id>
    <nct_id>NCT00005595</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease</brief_title>
  <official_title>Multicenter Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Hodgkin's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients&#xD;
      who have relapsed or refractory Hodgkin's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the efficacy of arsenic trioxide in terms of rate of response&#xD;
      (complete or partial remission), duration of response, relapse free survival, and overall&#xD;
      survival in patients with relapsed or refractory Hodgkin's disease. II. Evaluate the&#xD;
      toxicities of this agent in this patient population. III. Elucidate the mechanism of action&#xD;
      of this treatment by measuring induction of apoptosis and caspace activation when given to&#xD;
      these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients receive arsenic trioxide IV over 1-2 hours&#xD;
      daily for up to 60 days. After 4-6 weeks of rest, patients receive up to 5 additional courses&#xD;
      of therapy of 25 days each followed by 4-6 weeks of rest. Patients with a complete response&#xD;
      (CR) receive 1 additional course of 25 days after achieving CR. Treatment continues in the&#xD;
      absence of unacceptable toxicity or disease progression. Patients are followed monthly for 6&#xD;
      months, every 2 months for 6 months, every 3 months for 12 months, and then every 6 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to accrue subjects in a timely fashion.&#xD;
  </why_stopped>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">April 2002</completion_date>
  <primary_completion_date type="Actual">April 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">2</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed relapsed or refractory Hodgkin's disease&#xD;
        Relapsed after prior first line treatment with at least 2 regimens, such as:&#xD;
        Mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) Doxorubicin, bleomycin,&#xD;
        vinblastine, and dacarbazine (ABVD) MOPP/ABV Stanford 5 OR Refractory to a second line&#xD;
        regimen, such as: Mesna, ifosfamide, mitoxantrone, and etoposide (MINE) Etoposide,&#xD;
        methylprednisolone, high dose cytarabine, and cisplatin (ESHAP) High dose chemotherapy and&#xD;
        autologous or allogeneic stem cell transplantation At least 1 measurable lesion&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-2 Life expectancy: Not&#xD;
        specified Hematopoietic: Unless documented bone marrow involvement: WBC at least 4,000/mm3&#xD;
        Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL Renal:&#xD;
        Creatinine no greater than 2.0 mg/dL Other: Not pregnant or nursing Negative pregnancy test&#xD;
        Fertile patients must use effective contraception HIV negative No other prior malignancies&#xD;
        within the past 5 years except curatively treated basal cell or squamous cell carcinoma of&#xD;
        the skin or carcinoma in situ of the cervix No concurrent active infection requiring&#xD;
        antibiotics&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No concurrent&#xD;
        biologic agents No concurrent monoclonal antibodies No concurrent bone marrow&#xD;
        transplantation Chemotherapy: See Disease Characteristics No other concurrent chemotherapy&#xD;
        Endocrine therapy: Not specified Radiotherapy: No concurrent radiotherapy Surgery: Not&#xD;
        specified Other: No other concurrent anticancer agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin S. Tallman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>March 3, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2004</study_first_posted>
  <disposition_first_submitted>February 18, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 18, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 25, 2011</disposition_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

